ClinicalTrials.Veeva

Menu

Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Completed

Conditions

Stable Atherosclerotic Coronary Disease

Treatments

Dietary Supplement: Fish oil
Dietary Supplement: Krill

Study type

Interventional

Funder types

Other

Identifiers

NCT01092793
Krill-2010

Details and patient eligibility

About

Atherosclerotic coronary heart disease is a condition thought to involve low-grade inflammation. Several reports, clinical and epidemiological, have demonstrated that intake of fish oil may be beneficial in attenuating the inflammatory process. Still, however, there are lacking data in respect to whether differences in composition of various marine oils may influence the inflammatory status differently.

The hypothesis of the current study is that extract from the antarctic krill (Euphausia superba) is better than traditional fish oils when compared head-to-head with balanced composition of omega 3 content on inflammatory status.

Enrollment

60 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: 18-80 years
  • Sex: Male and female
  • Stable atherosclerotic coronary heart disease (heart attack >3 months ago or objectified angina pectoris).
  • No hospitalization for heart disease last 3 months.

Exclusion criteria

  • Unstable heart disease.
  • Heart failure NYHA class III and IV.
  • Previous valve and/or aortic surgery
  • Significant concomitant disease (i.e. diseases with known inflammatory activation - e.g. various autoimmune diseases, chronic infections, significant acute infections three weeks before or during the study, connective tissue disease, arthritis, chronic pulmonary disease or serious liver- or kidney-disease).
  • Simultaneous involvement in other clinical studies involving intervention.
  • Planned operation or other invasive procedures (e.g. PCI etc.) during the study period.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

60 participants in 3 patient groups

Krill
Active Comparator group
Treatment:
Dietary Supplement: Krill
Fish oil
Active Comparator group
Treatment:
Dietary Supplement: Fish oil
Control
No Intervention group

Trial contacts and locations

1

Loading...

Central trial contact

Leif Erik Vinge, MD, PhD; Lars Gullestad, Professor, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems